%D8%A3%D9%88%D9%83%D8%AA%D8%B1%D9%8A%D9%88%D8%AA%D9%8A%D8%AF%D8%A7%DA%A9%D8%AA%D8%B1%D8%A6%D8%AA%DB%8C%D8%AFOctreotidOctreotidOctreotideOctre%C3%B3tido%D8%A7%DA%A9%D8%AA%D8%B1%D8%A6%D8%AA%DB%8C%D8%AFOctr%C3%A9otideOctreotide%E3%82%AA%E3%82%AF%E3%83%88%E3%83%AC%E3%82%AA%E3%83%81%E3%83%89%EC%98%A5%ED%8A%B8%EB%A0%88%EC%98%A4%ED%8B%B0%EB%93%9C%D0%9E%D0%BA%D1%82%D1%80%D0%B5%D0%BE%D1%82%D0%B8%D0%B4OktreotidOktreotydOctreotida%D0%9E%D0%BA%D1%82%D1%80%D0%B5%D0%BE%D1%82%D0%B8%D0%B4OktreotidOktreotidOktreotidOctreotideQ419935%E5%A5%A7%E6%9B%B2%E8%82%BD
about
sameAs
P3781
Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal VaricesThe Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness ResearchSafety and Biological Activity of C2L-OCT-01 PR in Acromegalic PatientsGH, IGF-I and Somatostatin Analogues in Hepatocellular CarcinomaAMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine TumorsOctreotide in Severe Polycystic Liver DiseaseEfficacy/Safety of Octreotide Acetate in Patients With Uncontrolled AcromegalySafety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to ChemotherapyCabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With DocetaxelImaging Malignant Glioma With 68Ga-DOTATOC PET/CTA Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine TumorsSandostatin for Patients With Androgen Independent Prostate CancerRAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine CarcinomaStudy Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic PatientsFludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaOctreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal CancerTamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast CancerOctreotide and Doxorubicin in Treating Patients With Advanced CancerOctreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon CancerTolvaptan-Octreotide LAR Combination in ADPKDTreatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine TumorsA Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine NeoplasmsTerlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal SyndromeA Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid TumoursAutologous Fibrin Glues for Fistulas ClosureAcromegaly Combination Treatment StudyEffects of Sandostatin LAR® in AcromegalyRole of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft PancreasLong-term Safety and Efficacy Study of Octreotide Implant in Patients With AcromegalyWhole Body Dynamic 68Ga-DOTATOC PET/CT in Neuroendocrine TumorsA Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult VolunteersEffect of Hyperglycemia on Microvascular Perfusion in Healthy AdultsNorepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1.The Effect of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide on the Complications After Pancreatectomy. A Prospective, Multicenter Clinical TrialA Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus LanreotideMacro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic ShockRecurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin AnalogsEverolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received OctreotideEvaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation
P4844
Q1734755-852DC06D-1919-417F-8571-6D1ACE161BB6Q18554913-3C9BC029-99E7-4E33-A02C-43E1A824ECBCQ18556544-E9F51BE8-36CD-4027-B22F-62FBD6B8D4BBQ18557172-3782C9E3-F459-4671-A4D3-E191920DB798Q189580-152997A6-5653-4AE0-9F68-3FC7C6EFBCF6Q212961-B61F6B43-3A88-46D5-B681-6B05DA8C032AQ339547-24142D94-7B95-41A4-B810-AFD13FCFEFEA
P2176
Q61902285-5E825792-8B34-483C-A678-29178FE03539Q61909453-01175B8F-537B-4789-AFB8-80165632E832Q61914732-A0E487ED-7144-4812-A744-CFFE8A4E13B9Q61917535-B14FE05A-13BF-45ED-B9FA-200B264FC7DFQ61921358-E4884856-CBAA-4E70-A193-B1E2F17D9C5BQ61921455-A354C76B-3E80-453C-A53D-E2BEE3718FEAQ61932908-C7C8A29F-8D0E-464D-9630-E92085BFBCEEQ61934743-6E4C3727-AF2D-41D9-BF1F-85FB92179539Q61955809-973DD2D3-0845-4878-9E56-627099F838BAQ61957362-FFEC2981-BF88-4A39-85FC-DB1004D12C1AQ61966086-7CA0535E-5703-41FA-8818-1351B154C588Q61979268-AD71EB57-46DB-43D0-BC3B-32043DE5F610Q62104970-E2666E7C-58B1-4FB5-B844-6CCB91BE623FQ62110170-04100DBE-B902-48FA-8B3D-DED3D2D33268Q62110203-585012AA-3B00-4AB2-8A41-1C1C63821F99Q62110336-288124D7-682E-4776-BDC0-C8A97CEC42BFQ62110669-30A06CEE-CD3C-44CA-9F8E-7C74D1B98139Q62110980-39BD6403-7F91-492B-8381-DF012538A8DDQ62110982-E919F3FC-4F5D-49EE-89A8-5EB4FAB59910Q62811791-19904B16-8863-488D-9E09-D0C3387E189DQ62812517-5042D7F6-6FA3-4DA3-A416-3EE290329069Q62820133-A1549146-FEE6-4A72-B283-939B4AB90D1DQ63062596-F3D7640E-6184-4797-B34D-07C00862784BQ63315542-3DAEE861-4D4B-4586-B8B0-460B94395247Q63316401-8FC355D7-169E-4F98-AADD-2846F5A10AEEQ63319666-6B150790-B834-4B72-946B-16D9D2F6A7ADQ63321557-C9CC1506-48E1-4291-8FFA-20028D99F98DQ63337942-E3F5D248-7F03-4C4F-9AB0-AB51765788D2Q63339292-97F120F0-C1D4-43EB-81A6-FEF8799F32DBQ63396224-2E27E663-FAEF-4A3D-ABBE-5B325FA73683Q63397309-1F3A6B68-E40D-4805-9EAD-78D79D363507Q63397504-68430092-200B-4408-A875-CC151FB7A37DQ63400446-61306AD8-5545-45DD-A47B-BBA143780DFEQ63402620-FC0BEB64-3349-4D57-99D1-E10933B2764EQ63572659-43DA72EA-E301-4E3D-9BA3-1B0CD041D3E6Q63580369-DE633270-B33E-443F-A29C-3FC37FE0807CQ63582942-296ADC90-ACA4-4EC0-B865-5ED7D9D8ADF2Q63590953-EBE32E43-6834-4CA0-A5E0-6F10A1E8C411Q63593894-18EFD385-85C3-4856-83CD-982E5B80C7B3Q63594636-A8B2576F-2B9A-4960-866A-28A30F752C18
P4844
description
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Octreotid
@de
Octreotida
@pt
Octreotide
@en
Octreotide
@it
Octreotide
@nl
Octreotide
@vi
Octreótido
@es
Oktreotid
@nb
Oktreotid
@sh
Oktreotid
@sl
type
label
Octreotid
@de
Octreotida
@pt
Octreotide
@en
Octreotide
@it
Octreotide
@nl
Octreotide
@vi
Octreótido
@es
Oktreotid
@nb
Oktreotid
@sh
Oktreotid
@sl
altLabel
C49H56N10O10S2
@fr
Octreotido
@es
Octrotide
@cy
Octrotide
@en
SMS995
@en
Sandostatin LAR
@nb
Sandostatin
@de
Sandostatin
@nb
Sandostatin
@pl
Sandostatin
@pt
prefLabel
Octreotid
@de
Octreotida
@pt
Octreotide
@en
Octreotide
@it
Octreotide
@nl
Octreotide
@vi
Octreótido
@es
Oktreotid
@nb
Oktreotid
@sh
Oktreotid
@sl
P2175
P31
P486
P6366
P646
P662
P665
P683
P1296
P1987
3003.39.25
3004.39.26
P2017
C[C@@H](O)[C@@H](CO)NC(=O)[C@@ ...... (=O)N[C@@H]([C@@H](C)O)C(=O)N1
P2067
1,018.44048
P2115
N0000147950
P2175
P2275
octreotide
@en